Form 4: CytomX Therapeutics SVP Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher Ogden, SVP of Finance and Accounting at CytomX Therapeutics, sold 2,971 shares of common stock on March 19, 2024, to satisfy tax obligations related to vesting restricted stock units.
Summary
- On March 19, 2024, Christopher Ogden, the SVP of Finance and Accounting at CytomX Therapeutics, sold 2,971 shares of common stock.
- The sale was executed at a price of $2.0855 per share.
- The purpose of the sale was to cover tax or other government withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Ogden still beneficially owns 85,686 shares, which includes 60,310 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral event. The sale is for tax purposes and doesn't necessarily reflect a change in the executive's confidence in the company.
Industry Context
This is a routine Form 4 filing, indicating an insider transaction. It's common for executives to sell shares to cover tax obligations when restricted stock units vest. These transactions are closely watched by investors for insights into management's perspective on the company's value, although this particular sale is explicitly for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of stock sale transaction |
| 03/21/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.